EXACT SCIENCES CORP (EXAS) Stock News
NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD
EXAS Latest News, Press Relases and Analysis
Exact Sciences Hikes Its Full-Year Outlook. But There's One First-Quarter Drawback.
The company hiked its sales guidance for the year, but reported steeper-than-expected first-quarter losses.
Is The Trade Desk, Inc. (TTD) a Stock That Should Double in 3 Years?
We recently published a list of the 30 Stocks That Should Double in 3 Years. In this article, we are going to take a look at where The Trade Desk, Inc. (NASDAQ:TTD) stands against other stocks that should double in 3 years. On April 25, Kari Firestone, Aureus Asset Management executive chairman and co-founder, joined […]
Exact Sciences (EXAS) Reports Q1: Everything You Need To Know Ahead Of Earnings
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting results tomorrow after the bell. Here’s what to look for.
Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025
Certara, Inc. (CERT) Earnings Expected to Grow: Should You Buy?
Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: CERT
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: REGN
Exact Sciences (EXAS): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential
We recently published a list of Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential. In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ:EXAS) stands against Billionaire George Soros’ other small-cap stocks with huge upside potential. When a legendary investor like George Soros makes a move, Wall […]
2 Reasons to Like EXAS (and 1 Not So Much)
What a brutal six months it’s been for Exact Sciences. The stock has dropped 37.2% and now trades at $44.10, rattling many shareholders. This may have investors wondering how to approach the situation.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Mentions: HRTX
Exact Sciences Launches New Test To Monitor Cancer Recurrence: Retail’s Optimistic
Patients who test positive for circulating tumor DNA with the Oncodetect test during surveillance are 50 times more likely to experience cancer recurrence than those with negative results, the company said.
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Tap Into the Silver Economy Boom With These Aging Demographics Stocks
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups
Exact Sciences Schedules First Quarter 2025 Earnings Call
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Uncertainty has cast a pall over medical stocks, which are taking a "wait-and-see" approach to Trump's tariffs.
Should You Retain Exact Sciences Stock in Your Portfolio Now?
EXAS' solid focus on advancing new solutions bodes well for investors. However, a dull macroeconomic condition adds to the worry.
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week
Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among Stocktwits users for the week ended March 7, 2025.
